<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39308982</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>24</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-7762</ISSN><JournalIssue CitedMedium="Internet"><Volume>46</Volume><PubDate><Year>2024</Year><Month>Nov</Month></PubDate></JournalIssue><Title>The Lancet regional health. Europe</Title><ISOAbbreviation>Lancet Reg Health Eur</ISOAbbreviation></Journal><ArticleTitle>Efficacy and safety of interim oncology treatments introduced for solid cancers during the COVID-19 pandemic in England: a retrospective evidence-based analysis.</ArticleTitle><Pagination><StartPage>101062</StartPage><MedlinePgn>101062</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">101062</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lanepe.2024.101062</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The COVID-19 global pandemic placed unprecedented pressure on cancer services, requiring new interim Systemic Anti-Cancer Treatments (SACT) options to mitigate risks to patients and maintain cancer services. In this study we analyse interim COVID-19 SACT therapy options recommended in England, evaluating the evidence supporting inclusion and delineating how these have been integrated into routine cancer care.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We performed a retrospective analysis of interim Systemic Anti-Cancer Treatments endorsed by NHS England during the COVID-19 pandemic. Interim therapy options were compared to baseline (replacement) therapies by comparing data from the key pivotal trial(s) in terms of clinical efficacy and potential benefits (e.g., reduced immunosuppression or improved adverse effect profile) within the context of the pandemic. Furthermore, we evaluated the evolution of these interim SACT options, exploring if these have been integrated into current treatment pathways or are no longer accessible at the pandemic end.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">31 interim oncology treatment options, across 36 indications, for solid cancers were endorsed by NHS England between March 2020 and August 2021. Interim therapies focused on the metastatic setting (83%; 30/36), allowing greater utilisation of immune checkpoint inhibitors (45%; 14/31) and targeted therapies (26%; 8/31), in place of cytotoxic chemotherapy. Overall, 36% (13/36) of therapies could not have efficacy compared with baseline treatments due to a paucity of evidence. For those which could, 39% (9/23) had superior efficacy (e.g., overall survival), 26% (6/23) had equivocal efficacy and 35% (8/23) lower efficacy. 53% (19/36) of interim therapies had better or equivocal toxicity profiles (when assessable), and/or were associated with reduced immunosuppression. Almost half (47%; 17/36) of interim therapies did not have UK market authorisation, being classified as 'off label' use. Analysing access to interim options at the end of the pandemic (May 2023) identified 19 (53% 19/36) interim options were fully available, and a further four (11% 4/36) therapies were partially available.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="UNASSIGNED">Interim SACT options, introduced in England, across a range of solid cancers supported delivery of cancer services during the pandemic. Most interim therapies did not demonstrate superior efficacy, but provided other important benefits (e.g., reduced immunosuppression) in the context of the pandemic.</AbstractText><AbstractText Label="FUNDING" NlmCategory="UNASSIGNED">None.</AbstractText><CopyrightInformation>© 2024 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lythgoe</LastName><ForeName>Mark P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Surgery &amp; Cancer, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emhardt</LastName><ForeName>Alica-Joana</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Department of Health Services Research &amp; Policy, London School of Hygiene &amp; Tropical Medicine, London; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naci</LastName><ForeName>Huseyin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Health Policy, London School of Economics and Political Science, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krell</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgery &amp; Cancer, Imperial College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>King's College London, Institute of Cancer Policy, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aggarwal</LastName><ForeName>Ajay</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Health Services Research &amp; Policy, London School of Hygiene &amp; Tropical Medicine, London; Department of Medicine III, LMU University Hospital, LMU Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Reg Health Eur</MedlineTA><NlmUniqueID>101777707</NlmUniqueID><ISSNLinking>2666-7762</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cancer</Keyword><Keyword MajorTopicYN="N">Immune checkpoint inhibitors</Keyword><Keyword MajorTopicYN="N">Immunosuppression</Keyword><Keyword MajorTopicYN="N">Immunotherapy</Keyword><Keyword MajorTopicYN="N">NICE</Keyword></KeywordList><CoiStatement>ML, AE, RS, JK declare no conflicts of interest. HN reported receiving grants from the Commonwealth Fund, Health Foundation, UK Research and Innovation, and National Institute for Health and Care Research and personal fees from the World Health Organization, BMJ, and Pharmaceutical Group of the European Union outside the submitted work. AA is the recipient of an Advanced Fellowship NIHR300599 from the National Institute for Health Research. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health and Social Care.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>7</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>7</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>23</Day><Hour>5</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39308982</ArticleId><ArticleId IdType="pmc">PMC11415950</ArticleId><ArticleId IdType="doi">10.1016/j.lanepe.2024.101062</ArticleId><ArticleId IdType="pii">S2666-7762(24)00229-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Holshue M.L., DeBolt C., Lindquist S., et al. First case of 2019 novel coronavirus in the United States. N Engl J Med. 2020;382:929–936.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092802</ArticleId><ArticleId IdType="pubmed">32004427</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang W., Guan W., Chen R., et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21:335–337.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159000</ArticleId><ArticleId IdType="pubmed">32066541</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Zhu F., Xie L., et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31:894–901.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270947</ArticleId><ArticleId IdType="pubmed">32224151</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai A., Mohammed T.J., Duma N., et al. COVID-19 and cancer: a review of the registry-based pandemic response. JAMA Oncol. 2021;7:1882–1890.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8805603</ArticleId><ArticleId IdType="pubmed">34473192</ArticleId></ArticleIdList></Reference><Reference><Citation>Lythgoe M.P., Middleton P. Comparison of COVID-19 vaccine approvals at the US food and drug administration, European medicines agency, and health Canada. JAMA Netw Open. 2021;4:e2114531.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8233699</ArticleId><ArticleId IdType="pubmed">34170306</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323:1824–1836.</Citation><ArticleIdList><ArticleId IdType="pubmed">32282022</ArticleId></ArticleIdList></Reference><Reference><Citation>Lythgoe M.P., Middleton P. Ongoing clinical trials for the management of the COVID-19 pandemic. Trends Pharmacol Sci. 2020;41(6):363–382. doi: 10.1016/j.tips.2020.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2020.03.006</ArticleId><ArticleId IdType="pmc">PMC7144665</ArticleId><ArticleId IdType="pubmed">32291112</ArticleId></ArticleIdList></Reference><Reference><Citation>Einhorn L.H., Williams S.D., Loehrer P.J., et al. Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern cancer study group protocol. J Clin Oncol. 2016;7:387–391. doi: 10.1200/JCO198973387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO198973387</ArticleId><ArticleId IdType="pubmed">2465391</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayer R.J., Van Cutsem E., Falcone A., et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 2015;372:1909–1919.</Citation><ArticleIdList><ArticleId IdType="pubmed">25970050</ArticleId></ArticleIdList></Reference><Reference><Citation>Overview | COVID-19 rapid guideline: managing COVID-19 | Guidance | NICE. https://www.nice.org.uk/guidance/ng191</Citation></Reference><Reference><Citation>Guidelines | ESMO. https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic</Citation></Reference><Reference><Citation>AACR report on the impact of COVID-19 on cancer research and patient care: contents - cancer progress report. https://cancerprogressreport.aacr.org/covid/c19c-contents/</Citation><ArticleIdList><ArticleId IdType="pubmed">35140125</ArticleId></ArticleIdList></Reference><Reference><Citation>Passamonti F., Cattaneo C., Arcaini L., et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7:e737–e745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7426107</ArticleId><ArticleId IdType="pubmed">32798473</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta V., Goel S., Kabarriti R., et al. Case fatality rate of cancer patients with COVID-19 in a New York Hospital system. Cancer Discov. 2020;10:935–941.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7334098</ArticleId><ArticleId IdType="pubmed">32357994</ArticleId></ArticleIdList></Reference><Reference><Citation>He W., Chen L., Chen L., et al. COVID-19 in persons with haematological cancers. Leukemia. 2020;34(6):1637–1645.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7180672</ArticleId><ArticleId IdType="pubmed">32332856</ArticleId></ArticleIdList></Reference><Reference><Citation>Jee J., Foote M.B., Lumish M., et al. Chemotherapy and COVID-19 outcomes in patients with cancer. J Clin Oncol. 2020;38:3538–3546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7571792</ArticleId><ArticleId IdType="pubmed">32795225</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharafeldin N., Bates B., Song Q., et al. Outcomes of COVID-19 in patients with cancer: report from the national COVID cohort collaborative (N3C) J Clin Oncol. 2021;39:2232–2246.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260918</ArticleId><ArticleId IdType="pubmed">34085538</ArticleId></ArticleIdList></Reference><Reference><Citation>Poortmans P.M., Guarneri V., Cardoso M.J. Cancer and COVID-19: what do we really know? Lancet. 2020;395:1884–1885.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7259910</ArticleId><ArticleId IdType="pubmed">32479827</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman V., Hughes S., Carle C., et al. Are patients with cancer at higher risk of COVID-19-related death? A systematic review and critical appraisal of the early evidence. J Cancer Policy. 2022;33</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9169424</ArticleId><ArticleId IdType="pubmed">35680113</ArticleId></ArticleIdList></Reference><Reference><Citation>Lythgoe M.P., Krell J., Bower M., et al. From the European medicines agency to project Orbis: new activities and challenges to facilitate UK oncology drug approval following Brexit. Lancet Oncol. 2023;24:e150–e160.</Citation><ArticleIdList><ArticleId IdType="pubmed">36990613</ArticleId></ArticleIdList></Reference><Reference><Citation>MHRA products | home. https://products.mhra.gov.uk/</Citation></Reference><Reference><Citation>Good practice in prescribing and managing medicines and devices - professional standards - GMC. https://www.gmc-uk.org/ethical-guidance/ethical-guidance-for-doctors/good-practice-in-prescribing-and-managing-medicines-and-devices</Citation></Reference><Reference><Citation>Clark J.J., Dwyer D., Pinwill N., Clark P., Johnson P., Hackshaw A. The effect of clinical decision making for initiation of systemic anticancer treatments in response to the COVID-19 pandemic in England: a retrospective analysis. Articles Lancet Oncol. 2021;22:66–73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833889</ArticleId><ArticleId IdType="pubmed">33253639</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxter M.A., Murphy J., Cameron D., et al. The impact of COVID-19 on systemic anticancer treatment delivery in Scotland. Br J Cancer. 2021;124(8):1353–1356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8039028</ArticleId><ArticleId IdType="pubmed">33526866</ArticleId></ArticleIdList></Reference><Reference><Citation>Coronavirus (COVID-19): interim governance framework for cancer medicines in adults - gov.Scot Forscot. https://www.gov.scot/publications/coronavirus-covid-19-interim-governance-framework-for-cancer-medicines-in-adults/</Citation></Reference><Reference><Citation>Lee L.Y.W., Cazier J.B., Angelis V., et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395:1919–1926.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7255715</ArticleId><ArticleId IdType="pubmed">32473682</ArticleId></ArticleIdList></Reference><Reference><Citation>Conforti F., Pala L., Sala I., et al. Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis. BMJ. 2021;375 doi: 10.1136/BMJ-2021-066381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/BMJ-2021-066381</ArticleId><ArticleId IdType="pmc">PMC8689398</ArticleId><ArticleId IdType="pubmed">34933868</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>